Leptin, a hormone critical for normal food intake and metabolism, exerts a strong effect on appetite by acting in the mid-brain region as well as in the hypothalamus, according to a Yale School of Medicine study in Neuron. “Finding that…
The Thermo-expandable Metallic Stent For Managing Benign Prostatic Hyperplasia: A Systematic Review
The surgical management of LUTS or urinary retention secondary to BPH is not without risks, especially in the older patient or those with significant co-morbidities. The urethral stent was developed for these patients as an alternative to long-term urethral or…
Women Given Liver Transplants Outlive Male Recipients By Around 4 Years
Female liver transplant recipients outlive men given the same procedure by an average of 4.5 years, suggests research published ahead of print in Gut. And while younger people tend to live longest of all, they also stand to lose more…
Risk Of Irritable Bowel Syndrome Increased by Restricted Fetal Growth
Babies weighing less than the standard weight seem to be at significantly greater risk of developing irritable bowel syndrome or IBS, suggests research published ahead of print in the journal Gut. The Norwegian authors base their findings on 3334 twin…
AACR CEO Margaret Foti Receives Cancer Service Award
American Association for Cancer Research Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.) will receive the Association of American Cancer Institutes (AACI) Distinguished Service Award for her outstanding contributions to progress in cancer research. The award will be presented during…
Unprecedented Cross Institute Collaboration On Behalf Of Patients With Tourette Syndrome
Tourette Syndrome (TS) is an often disabling hereditary condition characterized by motor and phonic tics that today affects approximately 200,000 children and adults in the U.S. and Canada. In a meeting jointly sponsored by the National Institutes of Neurological Disorders…
Human Genome Sciences Reports Positive Results Of Phase 1 Clinical Trial Of CCR5 MAb In Patients Infected With HIV-1
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the results of a Phase 1 clinical trial of HGS004 (CCR5 mAb) demonstrate that it was well tolerated and exhibited antiviral activity in patients who are infected with HIV-1, the retrovirus…